Compare Stocks: ELDN, WVE, IMMX, and AVTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$16.34 -2.1%	$18.81	$10.70 ▼ $24.27	$879.00M	0.78	1.14 million shs	78,175 shs
ELDN Eledon Pharmaceuticals	$2.63 -0.9%	$3.40	$1.35 ▼ $4.60	$214.12M	0.93	1.19 million shs	95,850 shs
IMMX Immix Biopharma	$12.49 -1.8%	$11.38	$1.98 ▼ $15.10	$893.74M	0.2	1.27 million shs	168,146 shs
WVE WAVE Life Sciences	$4.37 -1.7%	$5.37	$4.38 ▼ $21.73	$862.09M	-1.3	3.78 million shs	344,197 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+0.66%	-2.85%	-15.32%	+13.54%	+47.31%
ELDN Eledon Pharmaceuticals	-0.75%	-4.68%	-26.80%	-32.40%	+9.05%
IMMX Immix Biopharma	+6.71%	+0.16%	+7.71%	+45.87%	+548.98%
WVE WAVE Life Sciences	-1.55%	-4.93%	-16.07%	-27.92%	-34.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$16.34 -2.1%	$18.81	$10.70 ▼ $24.27	$879.00M	0.78	1.14 million shs	78,175 shs
ELDN Eledon Pharmaceuticals	$2.63 -0.9%	$3.40	$1.35 ▼ $4.60	$214.12M	0.93	1.19 million shs	95,850 shs
IMMX Immix Biopharma	$12.49 -1.8%	$11.38	$1.98 ▼ $15.10	$893.74M	0.2	1.27 million shs	168,146 shs
WVE WAVE Life Sciences	$4.37 -1.7%	$5.37	$4.38 ▼ $21.73	$862.09M	-1.3	3.78 million shs	344,197 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+0.66%	-2.85%	-15.32%	+13.54%	+47.31%
ELDN Eledon Pharmaceuticals	-0.75%	-4.68%	-26.80%	-32.40%	+9.05%
IMMX Immix Biopharma	+6.71%	+0.16%	+7.71%	+45.87%	+548.98%
WVE WAVE Life Sciences	-1.55%	-4.93%	-16.07%	-27.92%	-34.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	175.99% Upside
ELDN Eledon Pharmaceuticals	2.33	Hold	$10.00	280.95% Upside
IMMX Immix Biopharma	2.78	Moderate Buy	$22.86	83.00% Upside
WVE WAVE Life Sciences	2.81	Moderate Buy	$22.31	411.17% Upside

Current Analyst Ratings Breakdown

Latest ELDN, WVE, IMMX, and AVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IMMX Immix Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $26.00
8/19/2026	WVE WAVE Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	IMMX Immix Biopharma	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$20.00 ➝ $19.00
8/10/2026	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $25.00
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
8/4/2026	WVE WAVE Life Sciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$27.00 ➝ $23.00
8/3/2026	WVE WAVE Life Sciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$13.00

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$59K	14,853.69	N/A	N/A	$4.49 per share	3.64
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$1.35 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
WVE WAVE Life Sciences	$42.73M	20.13	N/A	N/A	$3.10 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
ELDN Eledon Pharmaceuticals	-$45.62M	-$0.91	N/A	N/A	N/A	N/A	-149.63%	-50.84%	11/13/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
WVE WAVE Life Sciences	-$204.38M	-$1.09	N/A	N/A	N/A	-309.73%	-50.36%	-40.06%	11/9/2026 (Estimated)

Latest ELDN, WVE, IMMX, and AVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ELDN Eledon Pharmaceuticals	-$0.1580	-$0.27	-$0.1120	-$0.27	N/A	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
7/30/2026	Q2 2026	WVE WAVE Life Sciences	-$0.2998	-$0.34	-$0.0403	-$0.34	$7.45 million	$2.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
WVE WAVE Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	19.31	19.31
ELDN Eledon Pharmaceuticals	N/A	7.90	7.90
IMMX Immix Biopharma	N/A	25.13	25.13
WVE WAVE Life Sciences	N/A	9.99	9.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
ELDN Eledon Pharmaceuticals	56.77%
IMMX Immix Biopharma	11.26%
WVE WAVE Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	4.46%
ELDN Eledon Pharmaceuticals	9.60%
IMMX Immix Biopharma	30.30%
WVE WAVE Life Sciences	24.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
ELDN Eledon Pharmaceuticals	33	81.26 million	73.46 million	Optionable
IMMX Immix Biopharma	21	71.54 million	49.86 million	Optionable
WVE WAVE Life Sciences	317	197.05 million	149.17 million	Optionable

ELDN, WVE, IMMX, and AVTX Headlines

Recent News About These Companies

WAVE Life Sciences (NASDAQ:WVE) Reaches New 52-Week Low - What's Next?

September 16 at 5:02 AM | americanbankingnews.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 1-Year Low - Should You Sell?

September 16 at 4:00 AM | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Hits New 12-Month Low - Here's What Happened

September 10, 2026 | marketbeat.com

WAVE Life Sciences Ltd. $WVE Stock Holdings Boosted by Squarepoint Ops LLC

September 10, 2026 | marketbeat.com

Readystate Asset Management LP Purchases New Shares in WAVE Life Sciences Ltd. $WVE

September 7, 2026 | marketbeat.com

WAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Moderate Buy" from Analysts

September 4, 2026 | marketbeat.com

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

September 3, 2026 | globenewswire.com

WAVE Life Sciences (NASDAQ:WVE) Stock Price Down 4.3% - Time to Sell?

September 2, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Reaches New 12-Month Low - What's Next?

August 31, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Downgraded by Zacks Research to "Hold"

August 21, 2026 | marketbeat.com

WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in Stock

August 14, 2026 | insidertrades.com

Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover

August 13, 2026 | 247wallst.com

Wave Life Sciences: An Fairly Valued RNA Opportunity

August 12, 2026 | seekingalpha.com

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

August 11, 2026 | seekingalpha.com

Wave Life Sciences Completes Redomiciliation to Delaware

August 10, 2026 | finance.yahoo.com

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

August 10, 2026 | globenewswire.com

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

August 7, 2026 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB)

August 5, 2026 | theglobeandmail.com

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

August 5, 2026 | globenewswire.com

Wave Life Sciences to Present at Upcoming Investor Conferences

August 4, 2026 | globenewswire.com

Wells Fargo Reaffirms Their Buy Rating on Wave Life Sciences (WVE)

August 1, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, WVE, IMMX, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$16.34 -0.35 (-2.09%)

As of 10:14 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Eledon Pharmaceuticals NASDAQ:ELDN

$2.62 -0.03 (-0.94%)

As of 10:14 AM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Immix Biopharma NASDAQ:IMMX

$12.49 -0.23 (-1.81%)

As of 10:14 AM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

WAVE Life Sciences NASDAQ:WVE

$4.36 -0.08 (-1.69%)

As of 10:14 AM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELDN, WVE, IMMX, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELDN, WVE, IMMX, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELDN, WVE, IMMX, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, WVE, IMMX, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Eledon Pharmaceuticals NASDAQ:ELDN

Immix Biopharma NASDAQ:IMMX

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ELDN, WVE, IMMX, and AVTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ELDN, WVE, IMMX, and AVTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ELDN, WVE, IMMX, and AVTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELDN, WVE, IMMX, and AVTX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

Eledon Pharmaceuticals NASDAQ:ELDN

Immix Biopharma NASDAQ:IMMX

WAVE Life Sciences NASDAQ:WVE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools